Mustbio has published the preclinical study results of MB2033, a novel anti-PD-L1 x IL-2v bispecific fusion protein, in the journal “Cancer Immunology, Immunotherapy."

Highlights:

    • MB2033 is a novel anti-PD-L1 x IL-2 variant bispecific fusion protein

    • MB2033 acts through targeting-dependent mechanisms on PD-L1-expressing tumors. Simultaneously, it induces preferential activation and expansion of CD8⁺ T cells

    • In peripheral blood condition, MB2033 induces low immune cell expansion and inflammatory cytokine release, indicating a low peripheral toxicity risk

    • MB2033 treatment demonstrates a potent anti-tumor efficacy in colon cancer mouse model without severe adverse effects

    • MB2033 has a greater therapeutic benefit in cancer therapy and is promising therapeutic option to selectively trigger robust PD-L1 dependent cytotoxicity with less adverse effect